What were the primary drivers of revenue growth in the second quarter of 2001?

Revenue growth was primarily driven by the Companion Animal Group (CAG), which saw increased sales of veterinary reference laboratory services and instrument consumables. The Food and Environmental Division (FED) also contributed, with higher sales of water testing products and incremental revenue from the recent acquisition of Genera Technologies Limited.

How did the company's profitability change in the second quarter compared to the prior year?

Net income increased slightly to $9.97 million from $9.53 million in the prior year's second quarter. Diluted earnings per share rose to $0.29 from $0.26. However, the gross profit margin for the Companion Animal Group decreased to 46% from 48%, attributed to lower average unit prices for canine test kits and higher sales of lower-margin veterinary reference laboratory services.

What is the company's current liquidity position and how is it being utilized?

As of June 30, 2001, IDEXX Laboratories had $68.2 million in cash and short-term investments, and $156.7 million in working capital. The decrease in cash and short-term investments compared to the prior year-end was primarily due to $13.0 million spent on share repurchases and cash used for acquisitions. The company believes its current liquidity is sufficient for future operations.

What are the key risks and uncertainties facing IDEXX Laboratories?

The company faces risks related to rapid technological change and intense competition, potential patent infringements and litigation, reliance on single-source suppliers for certain products, regulatory hurdles in product commercialization (especially for animal health pharmaceuticals), and the integration of acquired businesses. Foreign operations also present risks related to currency fluctuations, differing regulatory standards, and political or economic changes in international markets.

IDXX 10-Q Quarterly Report Q2 FY2001 — Revenue, Net Income, EPS

Summary

IDEXX Laboratories, Inc. reported second quarter 2001 results with total revenue increasing by 8% year-over-year to $102.0 million, driven by strong performance in its Companion Animal Group (CAG). Net income saw a modest increase to $10.0 million, or $0.29 per diluted share. The company continues to invest in growth initiatives, including new product development and strategic acquisitions, which contributed to an increase in inventories and operating expenses. While the company demonstrated positive revenue growth, a slight decrease in gross profit margin for the CAG segment due to pricing adjustments and product mix warrants investor attention. The balance sheet shows a healthy working capital position, though cash and short-term investments have decreased due to share repurchases and acquisitions. The company reiterated its belief that current cash flow and reserves are sufficient for future operations. Investors should monitor the integration of recent acquisitions and the competitive landscape, particularly within the canine diagnostics market, as highlighted in the company's risk factors.

Key Highlights

1Total revenue for the second quarter of 2001 increased by 8% to $102.0 million, compared to $94.1 million in the prior year.
2Net income for the quarter was $9.97 million, a slight increase from $9.53 million in the same period last year. Diluted earnings per share were $0.29, up from $0.26.
3The Companion Animal Group (CAG) revenue grew 8% to $82.5 million, driven by veterinary reference laboratory services and instrument consumables.
4The Food and Environmental Division (FED) revenue increased 11% to $19.5 million, primarily due to water testing products and the acquisition of Genera Technologies.
5Operating cash flow for the six months ended June 30, 2001, was $8.4 million, down from $9.3 million in the prior year.
6The company repurchased approximately 0.6 million shares for $13.0 million during the first six months of 2001 as part of its stock repurchase program.
7Consolidated inventories increased significantly to $79.5 million from $65.9 million at year-end 2000, driven by contractually required purchases and anticipated product launches.

IDEXX LABORATORIES INC /DE Quarterly Report for Q2 Ended Jun 30, 2001

Summary

Key Highlights

Frequently Asked Questions